rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Association of Urine BDNF and NGF With Lower Urinary System Parameters
Status: Recruiting

Histologically, BPH is a benign proliferative process involving both epithelial and stromal elements and is characterised by progressive enlargement of the prostate. Symptom complex including increased frequency of urination, sudden feeling of urge to urinate, nocturia, difficulty in urinating, feeling of incomplete emptying of the bladder, decreased flow rate and intermittent urination are called lower urinary tract symptoms (LUTS). The most important cause of LUTS in men is BPH. Many structural and physiological changes occur in the lower urinary system with bladder outlet obstruction. Detrusor hypertrophy and bladder hyperactivity may occur due to bladder outlet obstruction. Although the density of afferent and efferent nerves in the bladder decreases after urethral obstruction, enlargement of their trunks indicates that changes occur in these nerves. In addition, changes also occur in the neural pathways of the central nervous system following lower urinary tract obstruction. Nerve growth factor (NGF) and brain derived neurotropin factor (BDNF) are trophic proteins that act as retrograde messengers between peripheral effector tissue and the nerves that innervate it. In peripheral tissues, the source of NGF and BDNF is presumed to be the target tissues innervated by nerves. Smooth muscle cells, fibroblasts, astrocytes and other cells synthesise NGF and BDNF in culture medium. Many potential stimuli that increase NGF in the lower urinary system have been identified. These are denervation, inflammation and mechanical tension. This information has led to the idea that autonomic innervation changes in the bladder may be related with changing NGF levels. Altered afferent and adrenergic innervation in the obstructed bladder increases the possibility that NGF plays an important role in this neural growth because this type of nerves are highly sensitive to this neurotrophin.

In this study, we investigated NGF ve BDNF levels in urine samples obtained before surgery (Transurethral Prostate Resection, Prostate Enucleation with Holmium Laser and Prostate Enucleation with Thulium Fibre Laser) and after removal of obstruction in patients with bladder outlet obstruction secondary to benign prostatic enlargement using ELISA method, We aimed to determine the role of NGF and BDNF in bladder outlet obstruction and bladder changes secondary to obstruction by comparing with control patients without obstruction.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  50-80 years Male Patients with bladder outlet obstruction secondary to benign prostate hyperplasia  Exclusion Criteria:  Known neurological disease Diabetes Urinary tract infection Previous prostate surgery Spinal Cord Trauma  7-Bladder stone 8-Cerebrovascular disease 9-Chronic Renal Failure 10-Ureteral stenosis - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - GenderBased: Yes - MinimumAge: 50 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Virtual Incentive Treatment for Alcohol
Status: Not yet recruiting

The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth >= 200 ng/mL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Had 2 heavy drinking episodes (assigned male at birth > 4 standard drinks (SDs), assigned female at birth > 3 SDs) or ≥14 SDs in the prior 14 days verified by PEth 16:0/18:1 biomarker > 20 ng/mL (indicates at least 2 heavy drinking episodes in past two weeks); Have a DSM-5 diagnosis of a current AUD as assessed by the Structured Clinical Interview for DSM-5; 18+ (individuals over 65 will be assessed for cognitive impairments) Are not receiving treatment for AUD Are able to complete virtual study visits via Zoom  Exclusion Criteria:  have a current diagnosis of severe substance use disorder (other than AUD, tobacco, and cannabis); PEth biomarker ≤ 20 ng/mL (indicates no heavy drinking in past month) inability to provide informed consent based on the UBACC or MacCAT-CR; alcohol withdrawal-related seizure or hospitalization in prior 12 months; psychiatrically or medically unsafe to participate, as assessed by the PI; and/or currently enrolled in alcohol treatment or another alcohol treatment study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
FallFitness Fallprevention Program for Older Adults
Status: Recruiting

The overall aim with this project is to collaborate with four organisations for retired persons located in a small region of middle Sweden. The project aims to test and evaluate a newly developed group-based fall prevention exercise program regarding the effects and experiences of both leading and participating in the intervention. The design of the study is a randomised controlled trial including a total of 100 participants (60+), 50 participants in the intervention and 50 participants in the control group.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  60 years of age Fluent in Swedish language in both speech and writing  Exclusion Criteria:  Physically weak, cannot sit upright without support and/or holding up the neck in a lying position and or rolls backwards Coronary artery disease and unstable angina Recently cataract treatment - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 60 Years - StdAgeList: Adult, Older Adult
Low Dose Atropine Eye Drops in Myopic Egyptian Children
Status: Not yet recruiting

Previous Studies reported that low concentration atropine eye drops may be effective in increasing the choroidal blood flow and thickness and this slows myopia progression.

purpose of the study is to compare changes in axial length, anterior chamber depth, choroidal thickness, central corneal thickness and anterior scleral thickness among myopic children receiving atropine 0.05% or 0.01% and placebo.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ranges from 6 to 12. Spherical equivalent ≥ -1.0 D.  Exclusion Criteria:  Astigmatism ≥ 3.0 D. History of allergy to atropine or positive skin allergy test. Ocular pathology otherwise myopia. Recent ocular surgery. Chronic systemic disease. Use of rigid contact lenses or soft contact lenses for 1 week before participating in the study - HealthyVolunteers: No - Gender: All - MinimumAge: 6 Years - MaximumAge: 12 Years - StdAgeList: Child
Comparison of Pain Relief Post Knee Arthroscopy Using IPACK + Adductor Canal Block vs. Adductor Canal Block Alone
Status: Not yet recruiting

In this study, the invistigators aim to compare postoperative analgesia effectiveness between combined interspace between the popliteal artery and posterior capsule of the knee block (IPACK) and Adductor canal block vs. Adductor canal block alone after Arthroscopic knee surgeries focusing on VAS score assessment at 8 hours postoperative.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Physical status: ASA 1 or 2 and candidates for spinal anesthesia undergoing Arthroscopic knee surgery. Age group: 20-40 years. No sex predilection.  Exclusion Criteria:  Patient refusal Physical status: ASA III or above. Patients with contraindications for spinal anaesthesia. Patients with history of drug allergies to study drugs. Evidence of local infection at site of injection. Neuromuscular pathology (example: - Multiple Sclerosis) - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 40 Years - StdAgeList: Adult
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
Status: Recruiting

This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female adults ≥ 18 years at the time of voluntary signing of informed consent. Pathologically confirmed unresectable or metastatic HER2 positive breast cancer previously treated with trastuzumab and taxane Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. Presence of at least one measurable lesion according to RECIST v1.1 Expected survival time ≥ 12 weeks. Patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study.  Exclusion Criteria:  Prior anti-HER2 ADC therapy. Previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring steroid therapy. Known serious hypersensitivity to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs. Multiple primary malignancies within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, autoimmune disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 (NCI-CTCAE v5.0) or baseline.  NOTE: Other protocol defined Inclusion/Exclusion criteria may apply. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine
Status: Not yet recruiting

Pre-eclampsia (PE) is one of the most frequent pregnancy complications and is one of the main causes of maternal and fetal morbidity and mortality in its severe form.control of blood pressure is of crucial importance to avoid maternal and fetal complications.Therapeutic modalities that can target the underlying pathophysiological changes and reverse the endothelial dysfunction could help to ameliorate the systemic manifestations in patients with severe PE. Either Intravenous labetalol and nitroglycerine as well as sublingual nifedipine have been frequantly used for the management of acute severe hypertension in PE

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The study will include 60 adult female patients ( 18 to 40 years old) with sever pre-eclampsia, who were being managed with MgSO4 loading and maintenance doses Severe hypertension was diagnosed by Systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥110 mmHg.  Mean arterial blood pressure ≥ 127 mmHg  Exclusion Criteria:  Patient refusal. Eclampsia Emenant eclampsia HELLP syndrome Chronic hypertension Patients who have chronic obstructive pulmonary disease. Patient with acute or chronic liver failure. Known allergy to the study medications - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 40 Years - StdAgeList: Adult
Retrolaminar Block Versus Tab Block in Abdomioasty
Status: Recruiting

The aim of the study is to compare the analgesic efficacy of Us guided retrolaminar block versus transversus abdominis plane block in patient under going abdominal plastic surgery

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - 90patients aged 18/65years of both sexes and asa physical status one two and three undergoing abdominal plastic surgery  Exclusion Criteria:  patient refusal Patient taking analgesia of chronic illness or have history of substance abuse Patient who are unable to describe their post operative pain Patient with history of coagulabathy Un cooperative patient Patient with known allergy to study drug Patient with infection at site needle puncture Patient with decompensated hepatic renal respiratory or cardiac disorder - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug
Status: Not yet recruiting

Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  All children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia  Exclusion Criteria:  Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with CHD affecting the pulmonary blood flow. - HealthyVolunteers: No - Gender: All - MinimumAge: 2 Months - MaximumAge: 18 Years - StdAgeList: Child, Adult
Do Patient Educational Videos Improve Pain and Recovery After Laparoscopic Hysterectomy?
Status: Recruiting

The use of multi-model patient education has been used in a variety of medical specialties to educate patients on expectations for various medical procedures and improve patients' understanding of their own health care. However, it is unknown what type of audio and/or visual materials work best in a given clinical setting. By surveying overall pain/post-operative recovery satisfaction we can measure how well our video intervention educates and reinforces post-operative management at home when compared to the current method of education that patients receive at the pre-operative visit prior to laparoscopic hysterectomy at this institution.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18y/o or older planned for a laparoscopic hysterectomy for benign indications  Exclusion Criteria:  inability to consent language other than English conversion to laparotomy, vNOTES (a type of laparoscopic assisted vaginal hysteroectomy) vaginal hysterectomy chronic opioid use prior to surgery - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.
Status: Recruiting

The study includes preterm infants who are being screened for ROP between August 1,2023 and August 1, 2024 in 94 neonatal intensive care units (NICUs) in Turkey. Infants with birth weight (BW) of >1500 g or ≥ 33 weeks' gestation who are screened for retinopathy of prematurity are included. The incidence of any ROP, severe ROP and treatment modalities will be determined. The risk factors for ROP development will also be evaluated.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Infants with BW >1500 g or ≥33 weeks' gestation who were determined to be at risk for ROP by the attending clinician and were screened for ROP.  Exclusion Criteria:  Neonates who died before the first ROP examination are excluded from the study. - HealthyVolunteers: No - Gender: All - MinimumAge: 28 Days - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Infants with BW >1500 g or ≥33 weeks' gestation who were screened for ROP. - SamplingMethod: Non-Probability Sample
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
Status: Recruiting

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  primary or recurrent HCC; synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC); pulmonary-only metastases >5 and ≤10; metastases diameter ≤ 5 cm; intrahepatic tumors ≤5, and tumor burden ≤1/2 liver volume; PVTT type Vp≤3; patients underwent first-line system therapy failure, the first-line system included tyrosine kinase inhibitor (TKI), such as Sorafenib or Lenvatinib, with or without PD-1 or PDL1 inhibitor; the intrahepatic tumors were effectively controlled and pulmonary metastases were no progression, and the controlled intrahepatic tumors were defined as partial or stable response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST); locoregional therapy (including TACE or HAIC) were also included; Child-Pugh class A or B; PS 0 or 1; no history of other malignancies.  Exclusion Criteria:  under 18 years or over 75 years; metastases >10 non-lung metastases; incomplete clinical data; metastases diameter > 5 cm; intrahepatic tumors > 5, and tumor burden > 1/2 liver volume; PVTT type Vp 4; lost to follow-up within 3 months. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Does Co-administration of Lactate to an Oral Glucose Tolerance Test Lower the Glucose Response?
Status: Not yet recruiting

To investigate whether co-administration of lactate with a glucose load affects postprandial glucose levels/handling, gastrointestinal hormones, gastric emptying, and appetite sensations in individuals with pre-diabetes when compared to placebo.

Hypothesis:

Oral lactate administration improves/lowers glucose excursions following an oral glucose tolerance test (OGTT) by stimulating insulin secretion and delaying glucose absorption.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  >40 years  Written and oral consent HbA1c 39-47 mmol/L  Exclusion Criteria:  Medicine with an impact on blood glucose and glucose metabolism Newly started medicine (<3 months prior to the inclusion time) Medicine changes (<3 months prior to the inclusion time and planned changes during the trial) Affected screening blood sample as evaluated by PI Hba1c > 47 Allergy to paracetamol Doesn't speak or understand Danish. Special diets - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 40 Years - StdAgeList: Adult, Older Adult
Drug-coated Balloon Treatment in Coronary Lesions
Status: Not yet recruiting

This study is multicenter registry for drug-coated balloon treatment for de novo and in-stent restenosis lesions

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Eligible patients are those with lesions in the coronary vessel tree who will be planned to be treated with drug coated balloon.  Exclusion Criteria:  Severe renal impairment ( Cr.Cl. < 45 ml/min ). Sever heart failure or liver cell failure . Patients with contraindications to coronary angiography or invasive procedures. Known allergy or intolerance to the medications or devices commonly used during PCI procedures. Severe comorbidities or conditions that may limit life expectancy or impact the ability to follow the study protocol. Pregnant or lactating women. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult
IDUS in CBD Stone Recurrence High Risk Patients
Status: Recruiting

This study is designed to observed CBD stones cases with high recurrence risks applying IDUS or not during ERCP.

Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy.

Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded.

Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  1.Clinical diagnosis of common bile duct stones 2.At least one of the following, diameter of CBD>1.5cm, or number of calculi>2, or lithotripsy during ercp  Exclusion Criteria:  1. Clinical diagnosis of liver or biliary malignant tumor. 2. Clinical diagnosis of duodenal malignant tumor 3. Failure or unexpected termination of ERCP 4. Surgery history of gallbladder or bile duct. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult